Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796265 | 0.80 | HRH4 (0.46) | HRH4MAP3K11HRH3DRD2DRD3 | |
| SCHEMBL5793661 | 0.78 | HRH4 (0.43) | HRH4HRH3DRD2DRD3DRD4 | |
| SCHEMBL5796234 | 0.77 | HRH4 (0.42) | HRH4HRH3DRD2DRD3CHEK1 | |
| SCHEMBL5797148 | 0.77 | HRH4 (0.41) | HRH4HRH3DRD2DRD3DRD4 | |
| SCHEMBL5793574 | 0.76 | HRH4 (0.39) | HRH4MAP3K11HRH3DRD2DRD3 | |
| SCHEMBL5794049 | 0.75 | HRH4 (0.45) | HRH4HRH3DRD2DRD3DRD4 | |
| SCHEMBL5793372 | 0.75 | HRH4 (0.42) | HRH4HRH3DRD2DRD3DRD4 | |
| SCHEMBL5917599 | 0.74 | CHEK1 (0.52) | HRH4HRH3DRD2DRD3DRD4 | |
| SCHEMBL5793998 | 0.73 | HRH4 (0.42) | HRH4HRH3DRD2DRD3DRD4 | |
| SCHEMBL5794526 | 0.73 | NPC1 (0.53) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006035308-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060069087-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2006-03-30 | — | — | US | claimed |
| WO-2006035308-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069087-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069087-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | HRH4 2/4885MAP3K11 1990/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.